SBIR/STTR Research Award
DETERMINING THE IMPACT OF SEMISYNTHETIC SAPONIN IMMUNOLOGIC ADJUVANT TITERQUIL ON INFLUENZA VACCINE IMMUNOGENICITY AND STABILITY
Award amount
$223,002Program and phase
SBIR · Phase IAward year
2017Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- ADJUVANCE TECHNOLOGIES INC
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- C6L6GD4QGWG9
- Solicitation number
- Not reported
- Topic code
- NIAID
Research abstract
The Contractor will develop TiterQuil a semi synthetic saponin adjuvant analog of QS for the purpose of improving the immunogenicity of commercially available flu vaccines Fluzone Sanofi Pasteur Fluvirin Seqirus and Flublok Protein Sciences
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- PRECLINICAL DEVELOPMENT OF SEMISYNTHETIC SAPONIN IMMUNOLOGICAL ADJUVANT TITERQUIL-1055 IN THE CONTEXT OF AN INFLUENZA VACCINE.
- Preclinical Development of Semisynthetic Saponin Immunological Adjuvant Titerquil-1055 in the Context of an Influenza Vaccine
- Large Scale Synthesis of the Next Generation Synthetic Saponin Adjuvant TiterQuil
- Large Scale Synthesis of the Next Generation Synthetic Saponin Adjuvant TiterQuil
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Manufacturing and Formulation Process Development for a Prophylactic Cholera Phage Cocktail
- A first-in-class product for the clearance of high-risk human papillomaviruses
- A Rapid, Point-of-Care Diagnostic to Identify Viable Sexually Transmitted Infections, Reduce Overtreatment, and Prevent Emerging Antibiotic Resistance
- Optimization, Pharmacokinetics, and Efficacy of an IgG Protease for the Treatment of Immune Thrombocytopenia and Other IgG-Mediated Autoimmune Diseases
- Nebulized ALX1 as a treatment for Pseudomonas aeruginosa infections in bronchiectasis patients
Research funding history
5 SBIR/STTR records share this UEI (2014–2020). Reported award amounts total $3,902,140. Reported amounts are not federal obligations.
Phases: Phase I, Phase II
Agencies: Department of Health and Human Services